Peanut Allergy StudyResearch Question:
Does ligelizumab (QGE031), an injectable, improve allergic reactions to peanuts?
Basic Study Information
Purpose:Study Reference #: Study00006879
This study is designed to determine if there is a way to decrease sensitivity to peanuts
in patients with a peanut allergy.
There are 3 phases in this study: 1) Screening – 3 visits over to 4 weeks, 2) Treatment
– 52-weeks - 17 visits with injections once a month, 3) Follow-up – 4 visits over
4 months. The study will involve skin prick tests/food challenges. You will be reimbursed
for your participation. Eligibility: Ages 6-55, diagnosed with a peanut allergy,
willing to commit to a partnership with our study team and the researchers at Novartis
as we work to help patients with peanut allergy!
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Allison Leadley
Phone: (585) 275-4640
Additional Study Details
This study is intensive. It lasts for about 17 months and has 24 study visits, including
skin prick tests and food challenges. We are looking for subjects dedicated to improving
the lives of people living with peanut allergy. Reimbursement is provided for each
study visit completed.
Number of Visits:
More than 10
$1,800 stipend if ALL study visits completed. Partial payment received after each
Learn More About These Conditions
More information about Anaphylaxis
More information about Peanut Hypersensitivity
Trial Not Found
The study you are looking for is not active at this time.
Thanks for answering our questions. A member of our study team will be in touch soon!
Sorry! You are not eligible for this trial.
Oops! Something went wrong.
Return to Search